UNSPSC 51182428: Denosumab

This classification denotes a monoclonal antibody with the molecular formula C6404H9912N1724O2004S50, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4EQZ6YO2HI, more generally known as denosumab. European Medicines Agency schedules denosumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB29173. The term DENOSUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 3, 2006, list 56. Most nations schedule Denosumab under HS 30021020 and SITC 54163.

SMILES:. As of Q4 2014, DENOSUMAB remains the US FDA Preferred Term for this commodity.. Denosumab bears US NLM identifiers UMLS ID C1690432 and NCI Concept Code C61313.

UNSPSC 51182428 Denosumab is a Commodity code representing a specific pharmaceutical product that state and local governments procure through cooperative purchasing agreements and multi-jurisdictional contracts. State and local procurement under this code centers on branded and generic pharmaceuticals distributed through established wholesaler networks to public health facilities, hospitals, clinics, and institutional care settings. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary recent issuing body pursuing this commodity. Cooperative purchasing alliances—multistate vehicles that pool procurement across member jurisdictions to achieve volume discounts and standardized pricing—dominate the recent activity, enabling state agencies, counties, cities, and special-purpose districts to access negotiated pharmaceutical pricing without conducting individual solicitations. Vendors must demonstrate compliance with current Good Manufacturing Practices (cGMP), the Drug Supply Chain Security Act (DSCSA), and FDA requirements, maintain relationships with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, and carry comprehensive insurance including commercial general liability of $5,000,000 per occurrence and network security and privacy liability of $2,000,000.

MMCAP's RFP S1070000015802 for Generic Multi Source Pharmaceuticals and OTC Products, issued January 20, 2026, with proposals due March 26, 2026, represents the most recent activity under this code and spans Minnesota and Oregon member jurisdictions. The evaluation emphasizes price competitiveness (75 percent weight), with 10 percent on fixed pricing for the contract term, 5 percent each on administrative fee data format compliance, EDI capability, and agreement to a 3 percent administrative fee. The contract term runs two years for new vendors with optional extensions at MMCAP's discretion, with incumbent amendments extending through June 30, 2028 and awarded products required available by May 15, 2026 for July 1, 2026 contract effectiveness. Vendors face performance penalties of $200 to $1,500 per violation for late reporting, missed onboarding timelines, or improper class-of-trade denials. No specific set-aside designations were identified in the available documentation, and no award values or budget ranges are disclosed.